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EMEA, that although all these drugs look promising at first
glance, they must be assessed in randomized studies to further
explore and refine their activity.
Another novel approach that currently attracts much atten-
tion is the pharmacologically based sequential drug combina-
tion of gemcitabine and docetaxel. As single agents for the
whole group of STS, both drugs are deemed inactive but with
respect to specific subtypes, docetaxel is suggested to exhibit
activity against angiosarcomas [8] and gemcitabine against
uterine leiomyosarcomas and high-grade undifferentiated
pleiomorphic sarcomas [9]. In a randomized phase II study,
the combination of gemcitabine and docetaxel was compared
to single-agent gemcitabine in 122 patients with advanced STS
who previously underwent 0–3 lines of chemotherapy [9]. Al-
though this study was not powered to establish differences be-
tween both arms and although no differences in the primary
endpoint (complete or partial response within 24 weeks, or
stable disease lasting longer than 24 weeks) were seen, the
gemcitabine-docetaxel combination was suggested to be supe-
rior, based on a longer progression-free and overall survival.
The number of each of the specific STS subtypes was too small
to assess differences between both regimens according to sub-
type, but it was suggested that gemcitabine-docetaxel was in
particular active against uterine leiomyosarcomas and high-
grade undifferentiated pleiomorphic sarcomas [9]. Despite the
preliminary nature of these data and the severe toxicities [9,
10], this regimen is currently widely applied to treat doxoru-
bicin- and/or ifosfamide refractory patients and is even used as
first-line therapy.
In the current issue of ONKOLOGIE, Ebeling et al. [11] report
on a single-center experience with this combination in heavily
pretreated patients with STS. No complete responses were en-
countered, partial responses were observed in 5 out of 34 pa-
tients. Of the 5 partial responses, 4 patients had a leiomyosar-
coma, but so had also the majority of patients (23 out of 34).
The group of soft tissue sarcomas (STS) is a very heteroge-
neous group of tumors comprising more than 40 different sub-
types. For patients presenting with advanced or metastatic dis-
ease, the prognosis is poor with a median overall survival of
10–12 months. First-line palliative chemotherapy is single-
agent doxorubicin [1, 2], with ifosfamide as a valid alternative
[3]. Several trials explored whether combination chemothera-
py yields improved outcomes over doxorubicin alone but until
now, there is no proven benefit for multi-drug combinations in
terms of prolonged overall survival while such combinations
are at the expense of increased toxicity [2]. Currently, there is
no established second-line therapy. 
Hopefully, this gloomy picture may shortly change due to ad-
vances made based on novel insights. One of these is the
recognition that the management of STS should be tailored
according to the STS subtype. Until recently, all STS subtypes
were treated equally. However, STS subtypes largely differ
from each other in terms of pathogenesis, clinical behavior,
and responses to systemic agents. It is therefore a logical step
to explore systemic agents in specific subtypes and the success
obtained with imatinib in patients with advanced GIST ro-
bustly underlines the correctness of this approach [4]. As a
consequence, more and more studies have been and are de-
signed to examine novel compounds in particular STS sub-
types. Largely through this approach, new therapies gleam at
the horizon for several of those subtypes including taxanes for
patients with angiosarcomas of the scalp [5], and trabectedin
(ecteinascidin-743) for patients with myxoid liposarcomas [6].
In addition, pazopanib, a tyrosine kinase inhibitor (TKI) di-
rected towards the vascular-endothelial growth factor recep-
tors (VEGFR) and the platelet-derived growth factor recep-
tors (PDGFR), exhibits anti-tumor activity in leiomyosarco-
mas, synovial sarcomas, and other STS subtypes, but not
against adipocytic sarcomas [7]. It should be emphasized,
 however, while trabectedin has recently been registered by
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Median time to progression was 2.4 months, median overall
survival 12.5 months and the progression-free rate at 3 months
was 38%. Since enhanced activity for this combination was
previously suggested in leiomyosarcomas [9, 10] and the ma-
jority of patients had leiomyosarcomas, the outcomes for this
subgroup were separately reported; median time to progres-
sion, median overall survival, and the progression-free rate at
3 months for this subgroup was 2.8 months, 17 months, and
45%, respectively. The study confirmed the considerable toxic-
ity of the gemcitabine and docetaxel regimen.
While interesting, the results of this study should be interpret-
ed with caution. Like in many other studies conducted in STS
patients, a strong emphasis is put on achieved responses. How-
ever, there is accumulating evidence that response rate is not
an adequate primary endpoint in studies in advanced STS pa-
tients. In a multi-variate analysis of 2,185 patients participat-
ing in European Organization of Research and Treatment of
Cancer Soft Tissue and Bone Sarcoma Group (EORTC-
STBSG) studies [12], a high tumor grade was associated with a
better response to chemotherapy but with a shorter overall
survival, a phenomenon that was confirmed in other series
[13]. This strongly suggests that tumors with a higher prolifer-
ation rate are initially more sensitive to chemotherapy, but be-
come resistant to therapy shortly thereafter, which is followed
by rapid progression resulting in a short overall survival. In
addition, many currently explored therapies such as VEGFR-
TKIs yield anti-tumor activity which is not clearly reflected in
tumor responses. The VEGFR-TKI sorafenib produced a low
response rate of only 10% in patients with renal cell carcino-
ma, but prolonged the progression-free and overall survival
compared to placebo [14]. Likewise, pazopanib, another
VEGFR-TKI, induced only a few responses in a phase II
study of the EORTC-STBSG, but yielded interesting progres-
sion-free and overall survival in several STS subgroups com-
pared to historical data [7]. As a result, response rates should
get a less prominent place in studies performed in advanced
STS patients. For phase II studies aiming to screen whether or
not a certain therapy exhibits activity in STS, the progression-
free rate (PFR) at a certain time point is considered a more
relevant end point. To be used in such studies, Van Glabbeke
et al. provided PFR at 3 and 6 months associated with active
and inactive therapies for both first and second line in ad-
vanced STS [15] based on a large EORTC-STBSG data-set.
Another comment that has to be made concerns the useful-
ness of studies as the study by Ebeling et al. First of all, the
study was retrospective in nature and such series are highly
prone to selection bias as can already be denoted from the ex-
ceptionally high number of patients with leiomyosarcomas in
the study. Furthermore, if a combination of drugs is explored,
a combination that includes at least one active drug as holds
true for gemcitabine-docetaxel, may yield activity based on
the activity of either agent. However, whether such a combi-
nation is superior compared to the respective single agents or
any other therapy remains unknown. It is therefore strongly
recommended to perform phase II-like studies with combina-
tions only in the context of a randomized design [16], as was
actually done in the randomized phase II study [9]. If the ex-
perimental arm is considered promising, the study can be ex-
tended into a phase III trial thereby decreasing the risk to ex-
pose patients to a potential suboptimal therapy, while money
and time is saved. There is now enough evidence that the gem-
citabine-docetaxel yields anti-tumor activity in STS. However,
this is based on a non-randomized phase II study [10], retro-
spective series, and on one randomized phase II study [9] that
was not powered to adequately assess survival differences.
There is thus an urgent need to perform randomized phase III
studies including the gemcitabine-docetaxel combination as
one of the experimental arms with appropriate stratification
for histologic STS subtypes. Only such a study can tell us
whether or not gemcitabine-docetaxel deserves a place in the
management of advanced STS patients. Of course the execu-
tion of studies in STS is hindered by the rare occurrence of
STS, but the story of imatinib in GIST has convincingly shown
that such problems can be overcome through intensive inter-
national collaboration offered by platforms such as the
EORTC and CONTICANET.
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